Evaluating an investigational medication called Cadisegliatin (TTP399) to reduce low blood sugar episodes and improve glucose management in adults with Type 1 Diabetes
Even with good insulin management, low blood sugar (hypoglycemia) episodes can still happen — and they can complicate your daily routine and long-term glucose goals.
The CATT1 clinical research study is evaluating whether a potential new oral treatment can help support more stable blood sugar in adults with type 1 diabetes.
vTv Therapeutics is studying an oral investigational medication designed to reduce low blood sugar episodes and improve A1C.
vTv Therapeutics Inc. is conducting a clinical research study to evaluate an investigational medication that may help reduce the risk of low blood sugar (hypoglycemia) and improve A1C in adults with type 1 diabetes.
This study will assess how well TTP399, an investigational oral drug, works in lowering the chance of low glucose events while also supporting improved overall glucose control. The clinical research study will also evaluate the safety and tolerability of TTP399 in adults living with type 1 diabetes.
Reducing low blood sugar episodes may help you feel better.
Improved A1C can support fewer glucose swings.
More stability may help make diabetes management feel easier.
The CATT1 clinical research study is evaluating an oral investigational treatment designed to help reduce low blood sugar events and improve A1C in adults with type 1 diabetes.
Approximately 9 months from start to finish
11 in-person visits and 11 convenient virtual visits
All study care provided at no cost to you
Payment provided for your time and travel expenses
Complete a brief survey to see if you may qualify for the study. Takes just a few minutes.
If eligible, you'll be contacted by qualified research staff in your area for more information.
Review the details and decide whether participation is a good fit for you.
Take the first step to see if you may qualify.
Participation lasts about 9 months and includes several phases:
How is the study drug taken? If eligible, you'll be randomly assigned to one of three groups. You may receive cadisegliatin at one of two dose levels, or a placebo (no active medication). The study drug is taken twice daily by mouth, with meals. All participants continue their regular insulin treatment.
A clinical research study is a type of research that tests how well a new medical approach works in people.
Before joining the clinical research study, you'll review detailed information and can ask questions. Participation is always voluntary.
No — this clinical research study is randomized and blinded, which means neither you nor the research team will know whether you're receiving the investigational drug or a placebo.
This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Glooko does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content.